Clinical trials begin with the Cuban drug for Alzheimer’s disease ›Cuba› Granma

NeuroEPO, a neuroprotective drug called NeuralCIM, is being researched by the Center for Molecular Immunology (CIM). Photo: Cubadebate

A Phase III clinical trial of the national Alzheimer’s drug NeuralCIM – the trade name of NeuroEPO – is about to begin in Cuba. Consultations on the classification of patients who will take part in the study began yesterday in Havana.
While this preliminary screening does not mean the full start of the clinical trial, it is an important step in moving forward in properly diagnosing patients and identifying the population to include, explained Dr. Kalet León Monzón, first deputy director of the Center for Molecular Immunology (CIM), speaking to the press on Wednesday.
Places in the capital where consultation appointments can be made include the Medical-Surgical Research Center (Cimeq), the Salvador Allende, Manuel Fajardo and Hermanos Ameijeiras hospitals and the Institute of Neurology.
Dr Leslie Pérez Ruiz, promoter of the Alzheimer’s clinical trial at CIM, explained that there is currently a database of over 400 patients, 371 of which are from Havana.
He said 310 health professionals have been identified who can call and get an appointment for a consultation that will determine if the patient has mild / moderate Alzheimer’s disease.
According to Dr Pérez Ruiz, Phase III of the study is expected to begin in September or October to evaluate the efficacy and safety of this nasal formulation.
He explained that NeuralCIM is being compared to donepezil, a drug approved by the US Food and Drug Administration since the 1990s, but that it is the first time that the patient in Cuba has undergone a molecular, rather than just a clinical, diagnosis of Alzheimer’s disease. .
He said a phase IV study will be conducted in the rest of the country in patients with mild / moderate disease phenotype (variant amnesia) whose diagnosis will be clinical only.
Dr Pérez Ruiz also explained that the medicine is used at home by the caregiver, who is trained in health facilities to use NeuralCIM correctly.

Leave a Comment